Zasadziński Konrad, Borkowska Aneta, Morysiński Tadeusz, Koseła-Paterczyk Hanna, Rutkowski Piotr, Spałek Mateusz Jacek
Department of Radiotherapy I, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Clin Transl Radiat Oncol. 2025 Apr 9;53:100954. doi: 10.1016/j.ctro.2025.100954. eCollection 2025 Jul.
Preoperative radiotherapy (RT) is used to improve local control (LC) and facilitate limb-sparing procedures in patients with localized soft tissue sarcomas (STS). While conventional preoperative RT delivers 50-50.4 Gy in 25-28 fractions, alternative hypofractionated regimens are under investigation. A 5x5 Gy regimen has been investigated in STS, but its long-term LC rates appear suboptimal. The aim of this study is to analyze the characteristics of patients with local recurrence (LR) after 5x5 Gy and to identify potential RT-related factors affecting efficacy.
We retrospectively analyzed patients who received 5x5 Gy and underwent surgery for localized extremity and truncal STS in three clinical trials and institutional records. Patient, tumor, and treatment characteristics were evaluated. We assessed the quality of RT plans and recurrence patterns.
Among 174 patients who experienced LR after 5x5 Gy, pleomorphic sarcoma (23 %), myxofibrosarcoma (17.8 %), and malignant peripheral nerve sheath tumor (12 %) were the most common pathologic diagnoses. No LR was observed in patients with myxoid liposarcoma. Almost all analyzed plans met the quality criteria. Most patients (86.2 %) had in-volume recurrences, suggesting inadequate tumor cell eradication rather than insufficient margins or poor target coverage. Dose equivalence analysis suggested that 5x5 Gy (EQD2 = 37.5 Gy for STS, assuming alpha/beta ratio of 4 Gy) may be insufficient, especially for radioresistant subtypes.
The primary factor contributing to LR after 5x5 Gy appears to be insufficient total dose. Future clinical trials should explore dose escalation beyond 5 Gy per fraction, except in myxoid liposarcoma where 5x5 Gy remains effective.
术前放疗(RT)用于改善局限性软组织肉瘤(STS)患者的局部控制(LC)并促进保肢手术。传统的术前放疗在25 - 28次分割中给予50 - 50.4 Gy,而替代的大分割方案正在研究中。一种5×5 Gy的方案已在STS中进行研究,但其长期LC率似乎不理想。本研究的目的是分析接受5×5 Gy放疗后局部复发(LR)患者的特征,并确定影响疗效的潜在放疗相关因素。
我们回顾性分析了在三项临床试验和机构记录中接受5×5 Gy放疗并接受局限性肢体和躯干STS手术的患者。评估了患者、肿瘤和治疗特征。我们评估了放疗计划的质量和复发模式。
在174例接受5×5 Gy放疗后发生LR的患者中,多形性肉瘤(23%)、黏液纤维肉瘤(17.8%)和恶性周围神经鞘瘤(12%)是最常见的病理诊断。黏液样脂肪肉瘤患者未观察到LR。几乎所有分析的计划都符合质量标准。大多数患者(86.2%)出现瘤内复发,提示肿瘤细胞清除不充分,而非切缘不足或靶区覆盖不佳。剂量等效分析表明,5×5 Gy(STS的等效剂量2 = 37.5 Gy,假设α/β比值为4 Gy)可能不足,尤其是对于放射抗拒亚型。
5×5 Gy放疗后导致LR的主要因素似乎是总剂量不足。未来的临床试验应探索每次分割剂量超过5 Gy的剂量递增,黏液样脂肪肉瘤除外,5×5 Gy对其仍然有效。